Michael Feigh is currently the Vice President at Gubra, where Michael leads scientific research and sales efforts focusing on NASH, NASH-HCC, and IPF. With previous experience at Nordic Bioscience A/S as a Research Scientist in the field of Diabetes/Obesity, Michael has a strong background in in vivo pharmacology and pre-clinical development. Michael's education includes a Ph.D. in Medicine from the University of Southern Denmark and a Master of Science in Human Physiology from the University of Copenhagen. Throughout their career, Michael has collaborated with various research groups and institutions to investigate metabolic effects and develop therapeutic solutions for metabolic diseases.
Sign up to view 1 direct report
Get started